Literature DB >> 28034553

Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters.

Patricia Dauer1, Alice Nomura2, Ashok Saluja2, Sulagna Banerjee3.   

Abstract

Every year, nearly 300,000 people are diagnosed with pancreatic cancer worldwide, and an equivalent number succumb to this disease. One of the major challenges of pancreatic cancer that contributes to its poor survival rates is the development of resistance to the standard chemotherapy. Heterogeneity of the tumor, the dense fibroblastic stroma, and the aggressive biology of the tumor all contribute to the chemoresistant phenotype. In addition, the acellular components of the tumor microenvironment like hypoxia, stress pathways in the stromal cells, and the cytokines that are secreted by the immune cells, have a definitive role in orchestrating the chemoresistant property of the tumor. In this review, we systematically focus on the role played by the different microenvironmental components in determining chemoresistance of pancreatic tumors.
Copyright © 2017 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemoresistance; Hypoxia; Metabolism; Tumor initiating cells

Mesh:

Substances:

Year:  2016        PMID: 28034553      PMCID: PMC5291762          DOI: 10.1016/j.pan.2016.12.010

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  78 in total

1.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases.

Authors:  C C Wykoff; N J Beasley; P H Watson; K J Turner; J Pastorek; A Sibtain; G D Wilson; H Turley; K L Talks; P H Maxwell; C W Pugh; P J Ratcliffe; A L Harris
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

Review 2.  The role of inflammation in pancreatic cancer.

Authors:  Simone Hausmann; Bo Kong; Christoph Michalski; Mert Erkan; Helmut Friess
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

3.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer.

Authors:  Peter J Campbell; Shinichi Yachida; Laura J Mudie; Philip J Stephens; Erin D Pleasance; Lucy A Stebbings; Laura A Morsberger; Calli Latimer; Stuart McLaren; Meng-Lay Lin; David J McBride; Ignacio Varela; Serena A Nik-Zainal; Catherine Leroy; Mingming Jia; Andrew Menzies; Adam P Butler; Jon W Teague; Constance A Griffin; John Burton; Harold Swerdlow; Michael A Quail; Michael R Stratton; Christine Iacobuzio-Donahue; P Andrew Futreal
Journal:  Nature       Date:  2010-10-28       Impact factor: 49.962

4.  Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras.

Authors:  Thomas B Brunner; Keith A Cengel; Stephen M Hahn; Junmin Wu; Douglas L Fraker; W Gillies McKenna; Eric J Bernhard
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

5.  Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.

Authors:  Yuhuan Zheng; Zhen Cai; Siqing Wang; Xiang Zhang; Jianfei Qian; Sungyoul Hong; Haiyan Li; Michael Wang; Jing Yang; Qing Yi
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

6.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

7.  Pancreatic CSCs and microenvironment.

Authors:  Matthias Ilmer; David Horst
Journal:  Genes Cancer       Date:  2015-09

8.  Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.

Authors:  Xianda Zhao; Wei Fan; Zhigao Xu; Honglei Chen; Yuyu He; Gui Yang; Gang Yang; Hanning Hu; Shihui Tang; Ping Wang; Zheng Zhang; Peipei Xu; Mingxia Yu
Journal:  Oncotarget       Date:  2016-12-06

9.  The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival.

Authors:  Daniel Delitto; Brian S Black; Heather L Sorenson; Andrea E Knowlton; Ryan M Thomas; George A Sarosi; Lyle L Moldawer; Kevin E Behrns; Chen Liu; Thomas J George; Jose G Trevino; Shannon M Wallet; Steven J Hughes
Journal:  BMC Cancer       Date:  2015-10-24       Impact factor: 4.430

10.  Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase.

Authors:  Moran Amit; Ziv Gil
Journal:  Oncoimmunology       Date:  2013-12-10       Impact factor: 8.110

View more
  44 in total

Review 1.  Overcoming transporter-mediated multidrug resistance in cancer: failures and achievements of the last decades.

Authors:  Miglė Paškevičiūtė; Vilma Petrikaitė
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

2.  Hypoxia alters the release and size distribution of extracellular vesicles in pancreatic cancer cells to support their adaptive survival.

Authors:  Mary C Patton; Haseeb Zubair; Mohammad Aslam Khan; Seema Singh; Ajay P Singh
Journal:  J Cell Biochem       Date:  2019-08-12       Impact factor: 4.429

3.  Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.

Authors:  Nagaraj S Nagathihalli; Jason A Castellanos; Purushottam Lamichhane; Fanuel Messaggio; Chanjuan Shi; Xizi Dai; Priyamvada Rai; Xi Chen; Michael N VanSaun; Nipun B Merchant
Journal:  Cancer Res       Date:  2018-08-28       Impact factor: 12.701

4.  Automated assessment of DNA ploidy, chromatin organization, and stroma fraction to predict prognosis and adjuvant therapy response in patients with stage II colorectal carcinoma.

Authors:  Zhixun Zhao; Xiaochen Zhang; Zhongwu Li; Yibo Gao; Xu Guan; Zheng Jiang; Zheng Liu; Ming Yang; Haipeng Chen; Xiaolong Ma; Runkun Yang; Zhao Lu; Hengchang Liu; Lujing Yang; Aiwen Wu; Shuangmei Zou; Xishan Wang
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

5.  Bromelain and acetylcysteine (BromAc®) alone and in combination with gemcitabine inhibit subcutaneous deposits of pancreatic cancer after intraperitoneal injection.

Authors:  Ahmad H Mekkawy; Krishna Pillai; Hyerim Suh; Samina Badar; Javed Akhter; Vahan Képénékian; Kevin Ke; Sarah J Valle; David L Morris
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

Review 6.  Hypoxia signaling in human health and diseases: implications and prospects for therapeutics.

Authors:  Zhen Luo; Mingfu Tian; Ge Yang; Qiaoru Tan; Yubing Chen; Geng Li; Qiwei Zhang; Yongkui Li; Pin Wan; Jianguo Wu
Journal:  Signal Transduct Target Ther       Date:  2022-07-07

Review 7.  Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma.

Authors:  Veethika Pandey; Peter Storz
Journal:  Expert Rev Anticancer Ther       Date:  2019-05-31       Impact factor: 4.512

8.  Hypoxia-Driven Oncometabolite L-2HG Maintains Stemness-Differentiation Balance and Facilitates Immune Evasion in Pancreatic Cancer.

Authors:  Vineet K Gupta; Nikita S Sharma; Brittany Durden; Vanessa T Garrido; Kousik Kesh; Dujon Edwards; Dezhen Wang; Ciara Myer; Beatriz Mateo-Victoriano; Sai Sundeep Kollala; Yuguang Ban; Zhen Gao; Sanjoy K Bhattacharya; Ashok Saluja; Pankaj K Singh; Sulagna Banerjee
Journal:  Cancer Res       Date:  2021-05-14       Impact factor: 12.701

Review 9.  Novel Anticancer and Treatment Sensitizing Compounds against Pancreatic Cancer.

Authors:  Gabrielle Wishart; Priyanka Gupta; Andrew Nisbet; Eirini Velliou; Giuseppe Schettino
Journal:  Cancers (Basel)       Date:  2021-06-11       Impact factor: 6.639

Review 10.  Stem Cells in the Exocrine Pancreas during Homeostasis, Injury, and Cancer.

Authors:  Sophie C Lodestijn; Sanne M van Neerven; Louis Vermeulen; Maarten F Bijlsma
Journal:  Cancers (Basel)       Date:  2021-06-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.